Neovasc Provides Corporate Update Following Clinical Data Release

Provided By Globe Newswire

Last update: Sep 20, 2022

New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease

VANCOUVER and MINNEAPOLIS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference (“TCT”) held September 16-19 in Boston.